Identifying c-fos Expression as a Strategy to Investigate the Actions of General Anesthetics on the Central Nervous System

Abstract

Although general anesthetics have been used in the clinic for more than 170 years, the ways in which they induce amnesia, unconsciousness, analgesia, and immobility remain elusive. Modulations of various neural nuclei and circuits are involved in the actions of general anesthetics. The expression of the immediate-early gene c-fos and its nuclear product, c-fos protein, can be induced by neuronal depolarization; therefore, c-fos staining is commonly used to identify the activated neurons during sleep and/or wakefulness, as well as in various physiological conditions in the central nervous system. Identifying c-fos expression is also a direct and convenient method to explore the effects of general anesthetics on the activity of neural nuclei and circuits. Using c-fos staining, general anesthetics have been found to interact with sleep- and wakefulness-promoting systems throughout the brain, which may explain their ability to induce unconsciousness and emergence from general anesthesia. This review summarizes the actions of general anesthetics on neural nuclei and circuits based on a c-fos expression.

1. INTRODUCTION

General anesthetics are widely used in clinics to produce a state in patients characterized by amnesia, unconsciousness, analgesia, and immobility while maintaining vital physiological functions [1, 2]. The application of general anesthetics has revolutionized surgical procedures since the middle 19^th century [2, 3]. More than 300 million patients worldwide undergo general anesthesia for medical procedures each year [4, 5]. Although thousands of studies have focused on the ways in which general anesthetics work, the exact molecular targets and neural circuits underlying the action of general anesthetics remain elusive [1, 2, 6-8].

Previous studies suggest that the modulation of general anesthetics on neural nuclei (e.g., the thalamus and hypothalamus) and networks (e.g., the thalamocortical loops and cortico-cortical loops) may be the key mechanism underlying the action of general anesthetics [2, 9, 10]. To investigate the modulation of general anesthetics on neural nuclei and circuits, a sensitive marker of neuronal activity is necessary. Numerous immediate early gene (IEG) products, such as c-fos, c-myc, Arc, Krox-24, fos-B, Egr1, Jun-D, Jun-B, and Jun-C, can serve as biomarkers of cell activity [11-14]. Among these IEG products, c-fos is the most commonly used [15, 16]. To the best of our knowledge, except for c-fos, very few other IEG products have been used to detect neural activity to determine the neural basis of general anesthesia or sleep-arousal [17-19]. Therefore, in this review, we focused on studies that investigated the neural basis of mechanisms of action of general anesthetics based on a c-fos expression. Using this method, many neural nuclei and circuits have been identified as the possible neural targets of general anesthetics that induce their pharmacological effects, including induction of unconsciousness, emergence from general anesthesia, and analgesia (Fig. 1).

Fig. (1).

The common brain nucleus, neural subtypes, and neural pathways for anesthetic actions and sleep-wakefulness behaviors based on changes in c-fos expression. The sagittal section through the rodent brain revealing that the brain nuclei related to general anesthesia-unconsciousness and emergence as identified by c-fos staining overlap completely with the known sleep-wakefulness nuclei. SON, supraoptic nucleus; TMN, tuberomamillary nucleus; LHb^Glu, glutamatergic neurons of lateral habenular nucleus; VLPO^GABA, GABA(γ-aminobutyric acid)-ergic neurons of ventrolateral preoptic nucleus; MnPO, median preoptic area; MPTA, mesopontine tegmental anesthesia area; PAG, periaqueductal gray; vlPAG, ventrolateral periaqueductal gray; A5, A6, A7 groups, the pontine noradrenergic cell groups; CeA^GABA, GABAergic neurons of central amygdala; PFH^Orx, orexinergic neurons of perifornical hypothalamus; BF^Orx, orexinergic neurons of basal forebrain; DRN^Ser, serotonergic neurons of dorsal raphe nucleus; PBN^Glu, glutamatergic neurons of parabrachial nucleus; increased expression of c-fos ↑ decreased expression of c-fos ↓. The arrows connecting any given regions A and B are neuronal pathways of the nucleus A on nucleus B.

In this review, we summarize the underlying neural substrates that mediate the action of general anesthetics, which were identified based on the strategy of c-fos staining. This review can potentially provide insights for future research on the neural basis of general anesthesia.

2. INDUCTION OF UNCONSCIOUSNESS BY GENERAL ANESTHETICS

Unconsciousness is the most pivotal pharmacological endpoint induced by general anesthetics. The mechanism by which general anesthetics induce unconsciousness remains unclear. Identifying the precise neural nuclei and/or circuits, especially the neuronal subtypes, that enable general anesthetics to induce unconsciousness will advance our basic understanding of general anesthesia. Neuronal activities can be primarily detected by c-fos expression in response to the induction of unconsciousness under general anesthetics. As a result, activation of sleep-promoting systems and inactivation of wakefulness-promoting systems may largely contribute to the induction of unconsciousness by both intravenous general anesthetics and volatile anesthetics.

The modulations of commonly used general anesthetics on c-fos expression, which have been demonstrated to be relevant to general anesthetic-induced unconsciousness, are summarized in Table 1.

Table 1.

The effects of general anesthesia on c-fos expression in brain nuclei related to anesthetic-induced unconsciousness.

-	Isoflurane	Sevoflurane	Halothane	Pentobarbital	Propofol	Chloral hydrate	Dexmedetomidine	Ketamine
VLPO	+[23, 25, 26]	-	+[25]	+[22, 23]	+[22]	+[23]	+[24, 41]	–[23]
MnPO	+[26]	-	-	-	-	-	-	-
SON	+[18]	-	-	-	+[18]	-	+[18]	+[18]
LHb	-	-	-	+[23, 64]	+[49]	+[23]	-	+[23]
PFH	-[17]	–[17]	Na [77]	–[76]	–[76]	-	Na [76]	-
TMN	-	-	-	–[22]	–[22]	-	-	-
MPTA	-	-	-	–[19]	-	-	-	-

Abbreviations: +, increased expression of c-fos; –, decreased expression of c-fos; NA, no effects on c-fos expression.

LHb, lateral habenular nucleus; MnPO, median preoptic area; MPTA, mesopontine tegmental anesthesia area; PFH, perifornical hypothalamus; SON, supraoptic nucleus; TMN, tuberomammillary nucleus; VLPO, ventrolateral preoptic nucleus.

2.1. Identifying c-fos Expression in Putative Sleep-promoting Nuclei Associated with General Anesthetic-induced Unconsciousness

2.1.1. Ventrolateral Preoptic Nucleus (VLPO) and Median Preoptic Nucleus (MnPO)

The VLPO and MnPO are specifically active during sleep and contain GABAergic and galaninergic neurons that project many arousal-promoting nuclei [20, 21]. The recent study indicated that activation of VLPO galaninergic neurons promoted sleep and heat loss in mice, whereas inhibition of VLPO galaninergic neurons reduced sleep [21]. Identified by increased c-fos expression, many general anesthetics have been found to activate putative sleep-active neurons in VLPO, including propofol [22], barbiturates [22, 23], chloral hydrate [23], dexmedetomidine [24], isoflurane [23, 25], and halothane [25], suggesting that VLPO may be a common target for multiple classes of general anesthetics.

Isoflurane (1.2%, 2 h) and halothane (1.0%, 2 h) significantly increased the expression of c-fos in the GABAergic neurons within the VLPO and decreased c-fos expression in the non-GABAergic neurons, whereas the non-immobilizer 1,2-dichlorohexafluorocyclobutane (F6) failed to affect the c-fos expression of VLPO, indicating that activation of GABAergic subpopulation neurons within the VLPO may be relevant to volatile anesthetic-induced unconsciousness [26]. Theoretically, the molecular targets that are sensitive to volatile anesthetics but not to the non-immobilizer, such as presynaptic voltage-gated sodium channel (Na_v) [27] and voltage-gated calcium channel (Ca_v) [28], are the underlying targets for volatile anesthetics to increase c-fos expression in GABAergic neurons of VLPO. This is likely due to presynaptic inhibition that increases glutamate release in the VLPO neurons. For the molecular basis, the volatile anesthetic sevoflurane should have bound multiple sites of Na_v [29]. However, the increased c-fos expression in the GABAergic neurons in the VLPO was not prevented by pretreatment with tetrodotoxin, which impairs trans-synaptic neurotransmission, suggesting that such modulation may result from the neuronal intrinsic activity. Previous studies have reported that sodium leak channel (NALCN) [30] and tandem pore potassium (K2P) channels [31] are two major contributors to neuronal intrinsic activities; thus, they may be involved in such modulation.

In addition, another study showed that isoflurane (0.6% or 1.2%, 2 h) and halothane (1.0%, 2 h) increased the absolute number of c-fos positive neurons in the VLPO when mice were sedated or unconscious [25]. Destroying VLPO neurons opposed the isoflurane-induced hypnosis [25]. Their electrophysiological data further revealed that the neurons of the VLPO were depolarized by isoflurane, which was believed to be responsible for promoting sleep in previous studies, while the neighboring non-sleep-promoting VLPO neurons were unaffected by isoflurane. Similar to the above study, this depolarization is found not solely due to a presynaptic inhibition to increase glutamate release onto VLPO neurons as previously hypothesized, but also a direct postsynaptic effect on VLPO neuronal intrinsic excitability by a reduction of background potassium conductance. This was demonstrated by a significant reduction of inward current when VLPO neurons were held at the reversal potential for potassium [25]. These findings indicate that isoflurane may selectively activate a subpopulation of neurons in the VLPO to cause hypnosis via both pre- and postsynaptic mechanisms. This has been summarized in detail in previous reviews as follows: volatile anesthetics and other general anesthetics may modulate neural connectivity and synaptic transmission via both pre- and postsynaptic mechanisms [32, 33]. For the molecular basis, isoflurane was supposed to increase intrinsic neuronal excitability by inhibiting background potassium conductance. K2P channels are a group of background K⁺ leak channels, including TASK, TREK, TWIK, TRESK, TALK, and THIK subfamilies, that regulate resting membrane potential (RMP) to control cellular excitability [34]. K2P channels are important contributors to the potency of volatile anesthetics. Isoflurane can induce unconsciousness via activation of TREK-1 and TASK [35, 36]. Moreover, K2P channels knockout animals exhibit resistance to volatile anesthetic-induced loss of consciousness [37]. Interestingly, recent studies have revealed the binding sites of isoflurane in the TREK1 K2P channel, including multiple neighboring residues on TREK1 TM2, TM3, and TM4 [38]. Another group of potassium channels, voltage-gated K⁺ channels (K_v), are also modulated by volatile anesthetics and play important roles in general anesthesia [39]. Emerging studies have found volatile anesthetic-binging sites within K_v. For example, sevoflurane was reported to bind open and closed structures at multiple sites in K_v1.2 [40].

Unlike VLPO, the effects of isoflurane and halothane on MnPO are not directly parallel to the effects on the VLPO [26]. Isoflurane, but not halothane, significantly increased c-fos expression not only in the GABAergic neurons but also in non-GABAergic MnPO neurons. Such neuronal activation is disrupted by blocking synaptic transmission ex vivo, indicating that MnPO may be recruited indirectly by isoflurane either through disinhibition or VLPO-mediated secondary activation.

For other general anesthetics, systemic delivery of dexmedetomidine (100 mg/kg) for 2 h induces sedative and hypnotic effects in mice, accompanied by elevated c-fos expression in the neurons of the VLPO and reduced c-fos expression in the cerebral cortex and subcortical wake-promoting systems [41]. Although both dexmedetomidine [24] and isoflurane [25] can elevate c-fos expression in the neurons of the VLPO, dexmedetomidine can reverse the neuronal depolarization of VLPO neurons induced by isoflurane in brain slices in vitro, likely resulting from direct hyperpolarizing actions through α2 adrenergic receptors of the postsynaptic VLPO neurons. Moreover, direct injection of dexmedetomidine into the VLPO can oppose the activation of the VLPO induced by 0.8% isoflurane in vivo, thus promoting emergence from isoflurane anesthesia [42]. Given that dexmedetomidine is a selective α2 adrenergic agonist, it is possible that α2 adrenergic signaling in the VLPO is implicated in mediating the arousal state via inhibition of sleep-active neurons. Therefore, general anesthetics may have conflicting effects on neurons within a specific nucleus. However, systemic rather than local delivery of dexmedetomidine may induce hypnosis by indirect depolarization of VLPO neurons via a net consequence of silencing inhibitory input to the VLPO [24].

Unlike most general anesthetics that can increase neuronal c-fos expression in VLPO, the patterns of c-fos expression induced by ketamine in anesthetic doses are similar to those under wakefulness [23]. Ketamine at a dosage equal to or just below the dosage used in clinical rat anesthesia (~150 mg/kg) decreases c-fos expression in VLPO, increases c-fos expression in the central arousal system, and induces arousal behaviors. This may be due to the reduced excitatory transmission of glutamate through targeting of the N-methyl-D-aspartic acid (NMDA) receptor. At a high dose of 300 mg/kg, ketamine produces prolonged sedation and decreases c-fos expression in the cerebral cortex and arousal system [23]. Thus, the predominant effect of ketamine at anesthetic dosages (75-100 mg/kg) appears to cause arousal behaviors in rats. This may explain why ketamine is often administered in combination with other sedative drugs, such as xylazine and dexmedetomidine.

2.1.2. Supraoptic Nucleus (SON)

The SON is part of the hypothalamic-pituitary axis and is located in the anterior hypothalamus [18, 43]. The SON regulates many physiological functions related to osmotic balance and vasoconstriction [44]. Very few studies have explored the function of SON in sleep-wakefulness regulation; however, the number of damaged cells was increased in the SON after severe sleep deprivation [43]. Recently, it was reported that the hypnotic effect of thalidomide, a nonbarbiturate hypnotic agent, may be associated with the activation of vasopressin-containing neurons in SON due to the significantly increased c-fos expression [45]. Interestingly, a recent study reported that SON neurons are commonly activated by various classes of general anesthetics, including isoflurane (1%-1.2%), propofol (180 mg/kg), ketamine (100 mg/kg), and dexmedetomidine (100 μg/kg) determined by increased c-fos expression, recording of brain slices, and in vivo recording of multichannel electrophysiology [18]. In this study, a distinct cluster of SON neurons was identified with strong c-fos positivity in response to these general anesthetics. Activation of these anesthesia-activated neurons (AANs) by chemogenetic or optogenetic stimuli strongly promoted slow-wave sleep or enhanced isoflurane anesthesia, whereas conditional ablation and/or inhibition of these AANs led to significant loss of sleep and shortened the duration of isoflurane anesthesia. In slice recordings, these four chemically distinct general anesthetics all depolarized the membrane potentials of the AANs within SON, which suggested that AANs within SON are the common neural substrates for various general anesthetics; however, the underlying molecular mechanisms of the depolarization remain unclear. General anesthetics may activate some G protein-coupled receptors (GPCRs) in AANs, thus increasing intracellular calcium release, thereby facilitating neuropeptide and hormone release to induce depolarization. These results reveal that the neuroendocrine system plays a crucial role in the regulation of general anesthesia. At the circuit level, these AANs within the SON project to the septum, anterior thalamus, and several other brain areas involved in arousal control, including the posterior lateral hypothalamus (PLH) [46], tuberomammillary nucleus (TMN) [47], supramammillary nucleus (MM) [48], lateral habenula (LHb) [49], periaqueductal gray (PAG) [50], ventral tegmental area (VTA) [51], median raphe nucleus (MnR), pedunculopontine nucleus (PPTg), and laterodorsal tegmental nucleus (LDTg) [52]. However, the exact role of such projections has not yet been determined in general anesthesia, which may differentially contribute to various classes of general anesthetics to produce distinct pharmacological endpoints, even though they all activate the AANs in SON. It is also important to acknowledge that SON primarily consists of neuroendocrine cells; future studies should determine the role of endocrine regulation of SON in the action of general anesthetics.

2.1.3. Lateral Habenula (LHb)

The LHb is a glutamatergic hub [53, 54] that receives inputs from various forebrain regions (e.g., prefrontal cortex, basal ganglia, preoptic, and lateral hypothalamus) [53-56] and projects to the rostromedial tegmental nucleus (RMTg) [57-59]. The LHb is involved in many neural functions such as depression, addiction, reward processing, motivation, sleep, and circadian rhythm [60-63]. For general anesthesia, it has also been suggested that LHb neurons are anesthesia-activated neurons (AANs) [18]. Hypnotic doses of ethanol, chloral hydrate, barbiturates, and ketamine induce c-fos expression in the LHb in mice [23, 64]. Propofol (7 mg/kg) induces c-fos expression in the LHb, and blocking LHb glutamatergic output prevents propofol-induced loss of righting reflex (LORR) and reduces the propofol-induced enhancement in electroencephalogram (EEG) power, suggesting that the glutamatergic pathway of the LHb may play a pivotal role in regulating the hypnotic effects of propofol [49]. As mentioned above, since the LHb also receives inputs from the SON and preoptic hypothalamus (e.g., VLPO), and these nuclei are the key nodes for anesthetic-induced hypnosis, SON/VLPO-LHb circuits may participate in the hypnosis induced by general anesthetics.

2.1.4. Nucleus Accumbens (NAc)

The nucleus accumbens (NAc), located within the ventral striatum, is known for its role in pleasure, reward, addiction, and pain processing [65]. The activity of the NAc also influences the effects of general anesthetics [66]. The adenosine A2A receptor (A2AR) in the NAc and the tuberomammillary nucleus has been reported to regulate physiological sleep [67, 68]. Systematic injection of a selective A2AR agonist significantly prolonged the duration of propofol-induced unconsciousness, accompanied by increased c-fos expression in the NAc [69]. However, the mechanism by which the A2AR agonist prolonged propofol-induced unconsciousness remains unclear. It is also unclear whether propofol anesthesia directly activates neurons in the NAc.

A recent study highlights the pivotal role of NAc in sevoflurane-induced unconsciousness [70]. Dopamine D1 receptor (D1R)-expressing neurons in the NAc were markedly inhibited under sevoflurane exposure (2%), evidenced by decreased Ca²⁺ signal intensity. However, the authors did not test the effects of sevoflurane on the c-fos expression in NAc D1R neurons. They further showed that activation of these neurons delays sevoflurane induction and induces emergence, whereas inhibition of these neurons accelerates sevoflurane induction and prolongs the emergence process. Their results provide the first evidence that NAc neurons directly modulate consciousness levels under unconsciousness induced by volatile anesthetics. Differential neural subpopulations within the NAc may contribute to the propofol- and sevoflurane-induced loss of consciousness; however, further confirmation is needed.

2.2. Identifying c-fos Expression in Putative Wakefulness-promoting Nuclei Associated with General Anesthetic-induced Unconsciousness

2.2.1. Tuberomammillary Nucleus (TMN)

The tuberomamillary nucleus (TMN) is the sole source of histaminergic neurons in the central nervous system (CNS), which commands the general state of consciousness [71]. The activity of TMN is high during wakefulness and low during sleep [71]. Intraperitoneal administration of GABAergic agonists or enhancers, such as muscimol (10 mg/kg), propofol (140 mg/kg), and pentobarbital (100 mg/kg), decreased c-fos expression in the TMN [22]. Accordingly, intracerebroventricular injection of muscimol into the TMN produced dose-dependent sedation, suggesting that GABAergic sedative components may be mediated by GABA_A receptors in the endogenous sleep pathway [22]. Conversely, gabazine, a GABA_A receptor antagonist, attenuated the sedative effects of these GABAergic agents by direct microinjection into the TMN. At the circuit level, TMN receives inputs from SON; therefore, SON-TMN projections may be involved in GABAergic general anesthetic-induced sedation or unconsciousness. This modulation of the GABAergic agonist on TMN also indicates the underlying involvement of the histaminergic system in general anesthesia.

2.2.2. Hypothalamic Orexinergic Neurons

Neurons expressing orexin are primarily located in the lateral hypothalamus, especially in the perifornical area, and are widely projected throughout the brain [72]. Orexinergic neurons in the perifornical area of the hypothalamus are critical for normal sleep, and a disruption of this system is known to cause a sleep disorder called narcolepsy [73, 74]. The orexinergic neurons in the hypothalamus also participate in regulating the effects of general anesthetics [17, 75]. The orexinergic neurons are inhibited by GABAergic drugs, including muscimol (5 mg/kg), propofol (100 mg/kg), and pentobarbital (50 mg/kg), as identified by a marked reduction in c-fos expression during anesthesia [76]. Regulating the neuronal activity of orexinergic neurons in the perifornical area can affect the concentration of GABAergic drugs for LORR [76]. These results imply that hypothalamic orexinergic signaling participates in the unconsciousness induced by GABAergic anesthetics.

Isoflurane and sevoflurane are also known to decrease c-fos expression in orexinergic neurons of the perifornical hypothalamus (PFH) [17]. Interestingly, halothane-induced hypnosis occurred without inhibition of dorsomedial and perifornical orexinergic neurons in mice, identified by no change in c-fos expression and electrophysiological recording in vivo [77]. Indeed, emergence from halothane anesthesia is not affected in orexin/ataxin-3 transgenic mice (loss of orexinergic neurons) [77]. Therefore, hypothalamic orexinergic signaling may differentially contribute to the actions of volatile anesthetics, which may be due to differences in protein binding targets [78] or varied modulatory ability on ion channels [79] or GPCRs [80].

2.3. Identifying c-fos Expression in Non-putative Sleep-wakefulness Nuclei Associated with General Anesthetic-induced Unconsciousness

2.3.1. Mesopontine Tegmental Anesthesia Area (MPTA)

The mesopontine tegmental anesthesia area (MPTA) includes the sub-peduncular tegmental nucleus and the dorsomedial part of the pontine reticular nucleus pars oralis [81]. The MPTA is flanked by the ventrolateral periaqueductal gray (PAG), reticular tegmental nucleus of the pons, cholinergic pedunculopontine tegmental nucleus (PPN), and median and paramedian pontine raphe [82]. MPTA is sensitive to GABAergic anesthetics, including pentobarbital, propofol, and etomidate [81, 83, 84]. Systemic administration of the classical GABAergic anesthetic pentobarbital (50 mg/kg) can suppress c-fos expression in the MPTA, indicating that neuronal activity of MPTA may be inhibited during GABAergic agent-induced anesthesia [19]. These inhibitory effects of classical GABAergic anesthetics may be due to the direct activation of postsynaptic GABA_A receptors. Indeed, localized injections of pentobarbital into the MPTA can induce a complete state of anesthesia, which appears to be mediated by a circuit of dedicated axonal projections to the nearby arousal nuclei of the brainstem and distant targets in the forebrain and spinal cord [81, 84, 85]; meanwhile, lesions in this region lead to insomnia [86]. These results provide direct evidence for the role of subcortical regions in mediating GABAergic anesthetic-induced unconsciousness, and MPTA may serve as the on-off switch of GABAergic anesthetic-induced anesthesia. However, it is not clear whether MPTA is also involved in the action of volatile anesthetics or modulation of sleep-arousal behaviors.

2.4. Identifying c-fos Expression in Cerebral Cortex Associated with General Anesthetic-induced Unconsciousness

In addition to the subcortical brain nucleus, it is widely known that the neural activity of the cerebral cortex itself also plays an important role in the general anesthetic induced-unconsciousness. Previous studies indicated that systemic administration of pentobarbital, a classical GABAergic sedative, caused widespread suppression of c-fos expression in the cerebral cortex of both mice and rats [19, 23, 64, 87], suggesting the activity of cerebral cortex was suppressed in the anesthetic-induced unconsciousness. However, the precise mechanism of how general anesthetics interfere with activity and/or connectivity of the cerebral cortex to induce unconsciousness is not well known. Disruption of either cortico-cortical loops [88] or thalamocortical loops [6] is the two long-standing hypotheses. A recent and important study indicated that different classes of general anesthetics (isoflurane, ketamine/xylazine, and urethane) induced unconsciousness by decoupling the information flow between layer 5 pyramidal neuron dendrites and their cell bodies, thus causing the breakdown of both cortico-cortical and thalamocortical feedback loops [10]. This finding provides the cellular mechanism that reconciles the two distinct hypotheses of cortico-cortical loops and thalamocortical loops.

3. EMERGENCE FROM GENERAL ANESTHESIA

Rapid recovery from unconsciousness is the most important characteristic of general anesthesia compared to other disruptions of consciousness, such as coma. Inadequate emergence, including emergence delirium and delayed emergence, may occur despite a stable state during surgery and general anesthesia [89], which can lead to delays in the operating room, the overall increase in costs, coughing, potential intracranial or intraocular pressure rise, respiratory accidents, and hemodynamic instability [89]. Up to 20% of general anesthesia awareness with recall episodes is attributed to the awakening phase [90]. Therefore, the neural mechanisms of emergence from general anesthesia are critically important but remain unclear. Generally, emergence from general anesthesia is considered a slow and passive process with the elimination of general anesthetics from their targets of action, which is the inverse process of anesthetic induction [91]. However, several studies have also indicated that anesthetic induction and emergence from general anesthesia are not inverse processes [17, 92]. Multiple neural nuclei and circuits have been shown to influence anesthetic emergence by the c-fos expression [17, 93, 94]. A major challenge is that expressional changes in c-fos protein are difficult to detect during the emergence period, as their appearance is delayed after stimulation [95]. Moreover, the methods of execution and anesthesia in animals may influence c-fos expression during emergence from anesthesia. Therefore, caution should be exercised when interpreting c-fos results associated with emergence from general anesthesia. The effects of various general anesthetics on the c-fos expression of neural nuclei related to anesthetic emergence are summarized in Table 2.

Table 2.

The effects of general anesthesia on c-fos expression in brain nuclei related to emergence from general anesthesia.

-	PFH Orexinergic Neurons	BF Orexinergic Neurons	DRN Serotonergic Neurons	PBN
Isoflurane	-[17]	-	-[112]	+[117]
Sevoflurane	-[17]	-	-	-
Propofol	-	-[93]	-	-

Abbreviations: -, decreased expression of c-fos under anesthetized status; +, increased expression of c-fos during emergence. BF, basal forebrain; DRN, dorsal raphe nucleus; PBN, parabrachial nucleus; PFH, perifornical hypothalamus.

3.1. Orexinergic Neurons in Hypothalamus and Basal Forebrain (BF)

Orexinergic neurons within the hypothalamus and BF play a critical role in the promotion and maintenance of wakefulness [75, 93, 96-99]. We have described the role of orexinergic neurons in anesthesia induction above. In this section, we will separately discuss their contribution to the emergence from anesthesia. Intracerebroventricular injection of orexinergic agonists and antagonists can also potentially alter emergence from general anesthesia [75, 100]. Isoflurane (1.25%, 2 h) caused a 30% reduction in the number of c-fos-expressing neurons, and sevoflurane (2.14%, 2 h) resulted in a 50% reduction in the number of c-fos-expressing neurons in the PFH of adult mice. Genetic and/or pharmacological impairment of orexin signaling dramatically delayed emergence from anesthesia by isoflurane and sevoflurane but did not alter anesthetic induction, indicating that orexinergic neurons in the PFH specifically mediate emergence from volatile anesthesia [17]. This study further demonstrated that isoflurane and sevoflurane had no effect on c-fos expression in adjacent melanin-concentrating hormone neurons, suggesting that wake-promoting orexinergic neurons are the specific targets of these anesthetics [17].

Orexinergic signaling is also involved in emergence from general anesthesia by intravenous general anesthetics. Similar to the results of c-fos expression changes in orexinergic neurons of the hypothalamus, propofol anesthesia also reduced the number of c-fos immunoreactive orexinergic neurons within the BF in rats, and the activities of orexinergic neurons in the BF were restored when the rats emerged from propofol anesthesia. Indeed, microinjection of orexin-A into the BF had no effect on the induction time; however, it facilitated the emergence from propofol anesthesia. Conversely, microinjection of the orexin-1 receptor antagonist into the BF delayed emergence from propofol anesthesia. These findings indicate that orexinergic signaling in the BF may specifically regulate the emergence, but not induction, of propofol anesthesia [93]. This also implies that emergence from anesthesia is not a simple converse process of anesthesia induction. Since hypothalamic orexinergic signaling appears to be involved in the unconsciousness induced by propofol, it would be interesting to determine whether induction and emergence of propofol anesthesia are mediated by orexinergic neurons of different neural circuits.

At the circuit level, a recent study found that optogenetic activation of orexinergic neurons in the perifornical lateral hypothalamic area or their terminals in the basal forebrain (BF) or locus coeruleus (LC) facilitated emergence from anesthesia by isoflurane, indicating that perifornical lateral hypothalamic area-BF/LC pathways are involved in the arousal from isoflurane anesthesia [101]. Other projects involving the perifornical lateral hypothalamic area must also modulate arousal from general anesthesia since it widely projects throughout the brain, such as the lateral hypothalamic glutamatergic projections to the LHb, which was recently shown to regulate anesthetic potency [102].

Cholinergic modulation in the BF also plays a pivotal role in emergence from general anesthesia. Acetylcholinesterase inhibitors may promote wakefulness partly by the direct activation of orexinergic neurons [17]. Moreover, inhibition of the excitatory nicotinic acetylcholine receptor (nAChR) is suggested to be responsible for the unconsciousness of general anesthesia [103]. At the molecular level, previous studies have identified the binding sites within the nAChR of several general anesthetics. Isoflurane persistently binds to three classes of sites in the transmembrane domain of nAChR [104], whereas propofol binds to an intra-subunit site in the transmembrane domain [105]. Using the bacterial homologue from Gloeobacter violaceus, researchers have revealed a common binding site for general anesthetics of propofol and desflurane, which pre-exists in the apo-structure in the upper part of the transmembrane domain of their protomers [103]. Collectively, these findings provide direct evidence that multiple ligand-receptors and ion channels are involved in the action of general anesthetics. Identification and specific modulation of the binding sites of general anesthetics will facilitate the exploration of the role of the brain nucleus under general anesthesia or sleep-arousal behaviors.

3.2. Serotonergic Neurons in the Dorsal Raphe Nucleus (DRN)

Orexinergic neurons project to the dorsal raphe nucleus (DRN) [72]. Serotonin (5-hydroxytryptamine, 5-HT) is the dominant monoamine neurotransmitter in the DRN [106] and plays a key role in the regulation of mood [107], appetite [108], sleep-arousal [109], memory [110], and learning [111]. Isoflurane (1.4%, 1 h) anesthesia reduced the number of c-fos immunoreactive serotonergic neurons in the DRN. This inhibitory effect was partially reversed by the administration of orexin-A in DRN, which enhanced arousal behaviors, suggesting that orexinergic neurons facilitate emergence from isoflurane anesthesia, at least partially, by activating serotonergic neurons in the DRN in rats [112]. These results reveal that hypothalamic orexinergic neurons-DRN serotonergic neurons projection may be a potential circuit that mediates emergence from general anesthesia induced by isoflurane.

3.3. Parabrachial Nucleus (PBN)

The parabrachial nucleus (PBN) promotes arousal [113, 114]. The majority of neurons in the PBN are glutamatergic [115] and project to numerous areas, including the basal forebrain, hypothalamus, thalamus, amygdala, and cortex [116]. The PBN is also able to regulate the emergence from general anesthesia induced by isoflurane. Muindi et al. found a selective increase in c-fos expression in the PBN neurons during emergence from isoflurane anesthesia (2.5% for 20 min + 0.9 - 1.0% for 40 min). Indeed, electrical stimulation of the PBN induced arousal and restoration of the righting reflex during continuous anesthesia under isoflurane [117], suggesting that recovery from isoflurane anesthesia may be related to the enhanced neural activity of PBN. However, since most neurons in the PBN are glutamatergic, further studies are needed to determine whether glutamatergic neurons in the PBN and the related neural circuitry are the definitive targets that control arousal from general anesthesia.

3.4. Paraventricular Thalamus (PVT)

Clinical observations indicate that the paramedian region of the thalamus is a critical node for controlling wakefulness, compared to other sites of the thalamus, since lesions of the paramedian thalamus show disorders of consciousness ranging from hypersomnolence to sleep-like coma [118-121]. In rodents, the homologous area of the primate paramedian thalamus includes many nuclei, such as the paraventricular thalamus (PVT), nucleus reuniens, mediodorsal nucleus, and interanteromedial thalamic nucleus [122, 123]. These nuclei have distinct connections [123-125] and are implicated in various neural functions, such as stress and anxiety, feeding behavior, drug-seeking activities, memory generation, arousal, and awareness processes [122, 126, 127]. Ren et al. recently observed a higher level of c-fos expression in the PVT than in the other regions of the paramedian thalamus in mice after extended wakefulness, indicating that PVT neurons exhibit high activity during wakefulness [94]. Furthermore, they found that glutamatergic neurons, the primary neural types in the PVT, exhibited high activity during wakefulness by in vivo fiber photometry or multichannel electrophysiological recordings. Additionally, activation of PVT glutamatergic neurons induced a transition from sleep to wakefulness and promotion of emergence from isoflurane anesthesia [94], suggesting that glutamatergic signaling within the PVT may underlie emergence from isoflurane anesthesia, and isoflurane anesthesia and sleep may share a common neural basis within the PVT. Therefore, activation of PVT neurons may be sufficient to induce wakefulness from an unconscious state in patients with paramedian thalamic stroke and/or anesthesia. At the circuit level, the hypothalamic hypocretin neurons-PVT-NAc projection regulates wakefulness; however, the authors did not report whether hypothalamic hypocretin neurons-PVT-NAc projection regulates emergence from isoflurane anesthesia. Nevertheless, the authors did not test the c-fos expression under isoflurane anesthesia. Therefore, the exact change in c-fos expression in PVT glutamatergic neurons during emergence from isoflurane anesthesia is unclear.

In addition to glutamatergic signaling, dopaminergic signaling is another neuronal subtype of the PVT [128]. Ao et al. recently reported that activation of dopaminergic signaling in the PVT also facilitated emergence from isoflurane anesthesia [129]. The number of c-fos-positive neurons was significantly higher in the PVT of mice that underwent passive emergence from isoflurane anesthesia than in those who underwent isoflurane anesthesia or oxygen. Injection of the D2-like agonist quinpirole into the PVT shortened the emergence time from isoflurane anesthesia, while administration of a D2-like antagonist prolonged the emergence time. Indeed, the number of c-fos positive neurons was significantly higher in the PVT of mice receiving quinpirole than in those receiving saline. However, neither quinpirole nor raclopride affected the induction time of isoflurane. These results indicate that dopaminergic signaling in the PVT may be selectively associated with the emergence from isoflurane anesthesia. However, more specific manipulation of dopaminergic neurons is needed to determine its role in emergence from anesthesia. It would be interesting to compare the relative contribution of glutamatergic and dopaminergic signaling in regulating emergence from general anesthesia.

3.5. Locus Coeruleus Nucleus (LC)

The LC is the main site for synthesizing norepinephrine (NE) in the brain [130]. As a key arousal node, the LC receives inputs from arousal-related orexinergic and histaminergic neurons and provides widespread noradrenergic innervation to the cerebral cortex and wake-promoting brain regions [130-135]. The LC-NE system plays a critical role in regulating sleep and wakefulness, as well as in general anesthesia [136-138]. One study showed that dexmedetomidine-induced LORR was abolished by selective knockdown of α2 adrenergic receptors in the LC [139]. Unexpectedly, general anesthesia by isoflurane or pentobarbital increased c-fos expression in the LC [23], suggesting that this arousal system may be activated by certain general anesthetics. The evidence supporting the role of LC in sleep-wakefulness and general anesthesia is that optogenetic or pharmacological activation of LC neurons causes an immediate transition from sleep to wakefulness and facilitates arousal from isoflurane-induced unconsciousness in rodents [136-138]. However, the exact contribution of LC activity, associated neural subpopulations, and synaptic functions in the balance of hypnosis and emergence during general anesthesia are unclear.

4. ANALGESIA

Analgesia is another important endpoint of general anesthetics and is critical for surgeries and invasive medical treatments [140]. Different classes of general anesthetics induce unequal pharmacological actions. GABAergic agents (e.g., propofol, etomidate, and barbiturates) produce profound hypnosis but weak analgesia [141]. In contrast, nitrous oxide, xenon, and ketamine produce analgesia but weak hypnosis [23, 141, 142]. Volatile agents (e.g., isoflurane and sevoflurane) are notable for their efficacy in inducing both hypnosis and immobility in a predictable manner [141]. The exact neural targets of general anesthetics to produce analgesia remain elusive. Generally, the spinal cord is recognized as the main target for general anesthetics to produce immobility (no response to nociceptive stimuli) [143, 144]. However, emerging evidence demonstrates that supraspinal nuclei of the CNS are also involved in the analgesic effects of general anesthetics [23, 140, 145], despite the fact that the relative contribution of the spinal cord and supraspinal nuclei to the general anesthetic-induced analgesia is unclear. The effects of various general anesthetics on c-fos expression in the spinal cord and brain nuclei that are related to analgesia are summarized in Table 3.

Table 3.

The effects of general anesthesia on c-fos expression in brain nuclei or the spinal cord related to analgesia.

-	-	Pentobarbital	Chlorate hydrate	Ketamine	Isoflurane	Propofol	Halothane	Nitrous oxide
Supraspinal regions	PAG	+[163]	-	-	-	+[163]	-	-
	Vc	+[163]	-	-	-	+[163]	-	-
	A5, A6, A7 groups	Na [23]	+[23]	+[23]	Na [23]	-	-	-
	vlPAG	Na [23]	-[23]	Na [23]	-[23]	-	-	-
	CeA	-	-	+[18]	+[18]	-	-	-
Spinal cord	Superficial dorsal horn	Na [147]/-[151]	-	-	-[148-151]	-[147, 151]	Na [148, 150]	-[150, 151]
	Deeper layers of dorsal horn	Na [147]	-	-	-	-[147]	-[150]	-[150]

Abbreviations: +, increased expression of c-fos; -, decreased expression of c-fos; NA, no effects on c-fos expression.

A5, A6, A7 groups, the pontine noradrenergic cell groups; CeA, central amygdala; PAG, periaqueductal gray; Vc, trigeminal spinal nucleus caudalis; vlPAG, ventrolateral periaqueductal gray dopamine cells;

4.1. Identifying c-fos Expression in Spinal Cord Neurons Associated with Analgesia under General Anesthesia

The analgesic or immobility action of volatile anesthetics is largely induced by modulation of the spinal cord [143, 146]. Isoflurane (1.8%) and propofol (10 mg/kg), but not halothane (0.9%-1.5%) and pentobarbital (20 mg/kg), suppressed c-fos expression evoked by nociceptive stimuli in the spinal superficial layers [147-149], indicating that these anesthetics may inhibit the transition of nociceptive sensory signals from the periphery to the spinal cord. Another study indicated that nitrous oxide (40% or 70%) and halothane (0.5% or 1.5%) suppress c-fos expression in the deeper layers (laminae V-X), but not in the superficial layers of the spinal cord, suggesting that nitrous oxide and halothane may target motor neurons in the deeper layers of the spinal cord instead of the sensory neurons in the superficial dorsal horn, which directly receive noxious inputs [150].

The modulation of c-fos expression in the spinal cord also varies at different anesthetic concentrations/doses. Takasusuki et al. showed that fentanyl (30 μg/kg), propofol (100 mg/kg), pentobarbital (50 mg/kg), isoflurane (2.4%), and nitrous oxide (66%) could reduce c-fos expression in the superficial dorsal horn of the spinal cord [151]. Taken together, these results also suggest that general anesthetics may selectively modulate neural targets associated with primary afferent inputs and motor signal outputs within different laminae of the spinal cord; however, it is unclear whether these effects are sufficient for volatile anesthetics to induce immobility in vivo.

4.2. Identifying c-fos Expression in Supraspinal Regions Involved in Analgesia Under General Anesthesia

Although the analgesic targets of general anesthetics in supraspinal regions are less clear than in the spinal cord, it has been suggested that supraspinal brain regions may participate in the analgesic effects of general anesthetics [23, 140]. The supraspinal brain maintains strong descending inhibition to nociceptive neurons in the spinal dorsal horn [23, 152, 153]. The ventrolateral periaqueductal gray matter (vlPAG) is the first identified supraspinal site that participates in descending pain modulation [154]. Subsequently, the rostral ventromedial medulla (RVM) is found to relay the projection from the PAG to the spinal cord [155, 156]. In addition to RVM, three pontine noradrenergic cell groups (A5-7) also receive inputs from the vlPAG [157] and project to the spinal dorsal horn [158]. The A5-7 cell groups have been reported to modulate endogenous antinociception [159] and antinociceptive effects of morphine [160], nitrous oxide [161], and isoflurane [162], via α2-adrenoceptors of neurons in the spinal dorsal horn, indicating that supraspinal regions may be potential analgesic targets under general anesthesia. Additionally, it is important to clarify the role of these regions and their interactional neural pathways, neural subtypes, and the molecular basis of the analgesic effects of general anesthetics.

4.2.1. Periaqueductal Gray (PAG) and Trigeminal Spinal Nucleus Caudalis (Vc)

Pentobarbital and propofol can increase neuronal c-fos expression in the periaqueductal gray (PAG) and trigeminal spinal nucleus caudalis (Vc) in rats [163]. Lu et al. showed that lesions of the ventrolateral PAG (vlPAG) attenuated the antinociceptive effects of both GABA_A-agents (e.g., chloral hydrate 300 mg/kg, and ethanol 1.0 g/kg) and ketamine (60 mg/kg) on noxious thermal stimulation [23], suggesting that vlPAG may be implicated in the analgesic effects of GABA_A-agents and ketamine. However, one study found that c-fos expression was very low in vlPAG with these anesthetics. This is probably due to the fact that the analgesic effects induced by these anesthetics may be primarily due to the suppression of inhibitory circuits (e.g., GABAergic signaling) within the vlPAG, which may fail to increase c-fos expression.

4.2.2. Noradrenergic A5-7 Groups (A5-7)

The analgesic effects of both classes of GABAergic agents and the NMDA receptor antagonist ketamine may be associated with endogenous brain systems [23]. Both GABAergic agents (e.g., chloral hydrate 350 mg/kg, and muscimol 5 mg/kg) and ketamine (60-300 mg/kg) induce c-fos expression in the spinally projecting noradrenergic A5-7 groups [23]. Like the vlPAG, lesions of the A5-7 groups attenuated the antinociceptive effects of these anesthetics on noxious thermal stimulation, suggesting that these general anesthetics can produce analgesia via A5-7 groups. Since the vlPAG innervates the A5-7 cell groups [157], it is possible that these classes of general anesthetics may inhibit GABAergic signaling in the vlPAG, thus releasing descending noradrenergic inhibition of A5-7 groups to suppress pain.

4.3. Identifying c-fos Expression in Brain Nucleus Associated with Analgesia under General Anesthesia

4.3.1. Central Amygdaloid Nucleus (CeA)

Central nuclei and circuits have been recently identified as being responsible for pain suppression of low-dose general anesthetics [140]. The authors used c-fos staining to screen neurons that remained strongly activated under isoflurane exposure. Three clusters were identified: CeA, oval division of the bed nucleus of the stria terminalis (ovBNST), and supraoptic nucleus (SON). As mentioned above, activation of SON neurons is related to the sedative components of general anesthetics, including isoflurane (0.5% or 1.5%, 2 h), ketamine/xylazine (ketamine 100 mg/kg + xylazine 10 mg/kg), and dexmedetomidine [18]. Isoflurane or intraperitoneal administration of ketamine and xylazine induced c-fos expression in GABAergic cells of CeA (CeA^GABA neurons). Accordingly, optogenetic activation of CeA^GABA neurons significantly suppressed both pain-elicited and self-recupera- ting behaviors, and alleviated neuropathic pain-induced mechanical hyperalgesia. Conversely, inhibition of the activity of CeA^GABA neurons exacerbated pain, produced strong aversion, and eliminated the analgesic effects of low-dose ketamine. Therefore, CeA^GABA neurons may serve as a potential target for general anesthetics to produce analgesia. It is unknown whether other subsets of CeA neurons that are involved in pain perception [164], such as neurons expressing somatostatin that do not overlap with CeA^GABA neurons, contribute to analgesia under general anesthesia. However, the authors did not prove that the activity of CeA^GABA neurons is also required for the analgesic effects of isoflurane in vivo due to the difficulty in performing behavioral tests. We believe that more brain nuclei related to general anesthetic-induced analgesia must exist and will be discovered in the future.

5. A BRIEF SUMMARY OF C-FOS EXPRESSION CHANGES IN OTHER NUCLEI UNDER GENERAL ANESTHESIA WHICH HAVE NOT BEEN DETERMINED TO BE ASSOCIATED WITH ANESTHETIC ENDPOINTS

A recent study indicated that pentobarbital produced a different influence on c-fos expression in subcortical regions of mice, among which 12 subcortical regions were activated during pentobarbital anesthesia [19]. For subcortical sites of rats, systemic pentobarbital anesthesia increased c-fos expression in the LHb; meanwhile, it reduced c-fos expression in the TMN, zona incerta (ZI), and nucleus raphe pallidus (Rpa) as compared to the awake group [64], which is not inconsistent with the results of Yatziv et al. [19]. Different exposure duration to general anesthetics may partially explain the inconsistent results of these two studies.

Sevoflurane anesthesia at a concentration of 2.9% ± 0.2% for 1 h induced a significant increase in c-fos expression in many brain regions in mice, most of which have not yet been proven to be associated with the action of general anesthesia [165]. C-fos was selectively expressed in GABAergic neurons in the lateral septal nucleus (LS), while no c-fos was expressed on GABAergic neurons of the thalamus [165]. Therefore, GABAergic neurons in the LS instead of the thalamus may be related to the unconsciousness induced by sevoflurane anesthesia. A brief summary of the c-fos expression changes in brain regions with undermined function under general anesthesia is presented in Table 4.

Table 4.

A brief summary of c-fos changes in brain regions with undetermined function under general anesthesia.

-	Isoflurane	Sevoflurane	Pentobarbital	Chloral hydrate	Ketamine
ZI	-	-	+[19]/-[64]	-	-
CC	-	-	-[19, 23, 64, 87]	-	+[23]
Cg	-[23]	+[165]	-[23]	-[23]	+[23]
PVHN	-	+[165]	+[19]	+[23]	-
LS	+[174]	+[165]	+[19]	+[23]	-
E-W	+[23]	+[165]	+[23]	+[23, 174]	+[23]
DG	-	+[165]	+[19]	-	-
Rpa	-	-	+[19]/-[64]	-	-
DMHN	-	+[165]	-	-	-
HC (CA1)	-	+[165]	-	-	-
AHN	-	+[165]	-	-	-
MT	-	-	-	-	+[23]

+, increased expression of c-fos; -, decreased expression of c-fos; NA, no effects on c-fos expression.

AHN, arcuate hypothalamic nucleus; CC, cerebral cortex; Cg, cingulate cortex; DG, dentate gyrus; DMHN, dorsomedial hypothalamic nucleus; E-W, Edinger-Westphal nucleus; HC, hippocampus; LS, lateral septum; MT, midline thalamus; PVHN, paraventricular hypothalamic nucleus; Rpa, nucleus raphe pallidus; ZI, zona incerta.

6. THE USE OF OTHER IMMEDIATE EARLY GENE PRODUCTS IN THIS FIELD

Numerous IEG products, such as c-fos, c-myc, Arc, Krox-24, fos-B, Jun-D, Jun-B, and Jun-C, can be used as biomarkers for neuronal activities [11-14]. In most cases, expressional changes of different IEG show the same trend in response to stimuli. For instance, Chastain-Potts et al. showed that sevoflurane exposure induces upregulation of Arc and Jun-B mRNA expression in the subiculum, which is crucial for synaptic plasticity and normal neuronal development [11]. Etomidate reduces the protein expression levels of memory-associated IEG in the rat hippocampus, including Arc, c-fos, and Egr1 [13]. However, there is some evidence that reveals distinct expression patterns in IEG under the same stimuli. Propofol increases c-fos mRNA but decreases Jun-C mRNA in rat brains [12]. Marota et al. showed that pentobarbital and halothane had select effects on c-fos and Jun-B mRNA expression in rat brains [166]. The related function may determine the expressional changes under a specific stimulus. Indeed, phosphorylation of extracellular signal-regulated protein kinase (ERK) is rarely used as a marker of neural activation. However, numerous studies have demonstrated that phosphorylation of ERK can induce the expression of its downstream proteins c-fos and that ERK phosphorylation/c-fos signaling is involved in many biological processes [167-169], including general anesthesia [170]. Although a number of IEG products have been detected in multiple biological processes associated with stress [171], memory [172], pain [173, 174], and general anesthesia [12], c-fos is still the most commonly used indicator of neural activation.

CONCLUSION AND FUTURE PERSPECTIVES

Despite a number of brain nuclei and neuron subtypes, as well as anesthetic binding sites, using a combination of techniques both in vitro and in vivo have emerged. The complex neuronal pathways in the CNS response to general anesthesia are less clear. Finding the link between molecular targets, neural circuits, and anesthetic-related endpoints remains challenging. Collectively, most evidence indicates that the brain nuclei identified by c-fos staining related to general anesthesia-unconsciousness and emergence overlap well with the known sleep-wakefulness nuclei, respectively. Previous work also suggests that comparisons with the features of natural sleep help to understand how general anesthetics affect neuronal pathways [2]. Our review provided a map of c-fos expression changes related to different components of action of various general anesthetics in the CNS and revealed several involved neuronal pathways, which may serve as a resource for future studies focusing on the neural basis of general anesthesia.

For future studies, unbiased screening of the brain regions throughout the brain under general anesthesia and sleep-wakefulness nuclei using c-fos expression is still helpful. Subsequently, it is possible to create a map of c-fos-related changes in all brain regions. Additionally, since c-fos protein expression is relevantly delayed, we also recommend timely detection of the dynamic changes of c-fos expression in brain nuclei, especially the neuronal type, throughout the brain to uncover the neural circuits underlying general anesthesia. In addition, multifaceted approaches that link molecular targets with neural subpopulations, neural circuits, and integrated endpoints are critical to determining the mechanism of action of general anesthetics.

LIST OF ABBREVIATIONS

A2AR

Adenosine A2A Receptor

A5, A6, A7 groups

The Pontine Noradrenergic Cell Groups

AANs

Anesthesia-Activated Neurons

AHN

Arcuate Hypothalamic Nucleus

BF

Basal Forebrain

Cav

Voltage-gated Calcium Channel

CC

Cerebral Cortex

CeA

Central Amygdala

Cg

Cingulate Cortex

CNS

Central Nervous System

D1R

Dopamine D1 Receptor

DG

Dentate Gyrus

DMHN

Dorsomedial Hypothalamic Nucleus

DRN

Dorsal Raphe Nucleus

ERK

Extracellular Signal-Regulated Protein Kinase

E-W

Edinger-Westphal Nucleus

F6

1,2-dichlorohexafluorocyclobutane

GABA

Gamma-aminobutyric Acid

GPCRs

G Protein-coupled Receptors

HC

Hippocampus

IEG

Immediate Early Gene

K2P

Tandem Pore Potassium Channels

Kv

Voltage-gated K⁺ Channels

LDTMN

Laterodorsal Tegmental Nucleus

LDTg

Laterodorsal Tegmental Nucleus

LH

Lateral Hypothalamus

LHb

Lateral Habenular Nucleus

LORR

Loss of Righting Reflex

LS

Lateral Septum

MM

Supramammillary Nucleus

MnPO

Median Preoptic Area

MnR

Median Raphe Nucleus

MPTA

Mesopontine Tegmental Anesthesia Area

MT

Midline Thalamus

nAChR

Nicotinic Acetylcholine Receptor

NALCN

Sodium Leak Channel

Nav

Voltage-gated Sodium Channel

NE

Norepinephrine

NMDA

N-methyl-D-aspartic Acid

PAG

Periaqueductal Gray

PBN

Parabrachial Nucleus

PFH

Perifornical Hypothalamus

PFLH

Perifornical Lateral Hypothalamus

PLH

Posterior Lateral Hypothalamus

PPN

Pedunculopontine Tegmental Nucleus

PPTg

Pedunculopontine Nucleus

PVHN

Paraventricular Hypothalamic Nucleus

RMP

Resting Membrane Potential

RMTg

Rostromedial Tegmental Nucleus

Rpa

Nucleus Raphe Pallidus

RVM

Rostral Ventromedial Medulla

SON

Supraoptic Nucleus

TMN

Tuberomammillary Nucleus

Vc

Trigeminal Spinal Nucleus Caudalis

vlPAG

Ventrolateral Periaqueductal Gray Dopamine Cells

VLPO

Ventrolateral Preoptic Nucleus

VTA

Ventral Tegmental Area

ZI

Zona Incerta

CONSENT FOR PUBLICATION

Not applicable.

FUNDING

This work was supported by the grant No. 2020YFC2008402 (to C.Z.) from the National Key R&D Program of China and No. 81974164 and 81771486 (to C.Z.) from the National Natural Science Foundation of China (Beijing, China).

CONFLICT OF INTEREST

The authors declare no conflict of interest, financial or otherwise.